UCB

The landscape of gene therapy is burgeoning with possibilities, offering promising advancements to patients with genetic disorders. In a revealing conversation with European Pharmaceutical Review Magazine, Roger Palframan, head of U.S. research at UCB, sheds light on the current trends, key developments, and future disruptors in gene therapy. His insights offer a glimpse into the potential of gene therapies. You can read the full interview 👉https://lnkd.in/exhVR3kp

At UCB, we measure our progress in access to medicines and continually look at what initiatives we should be working on to improve. Read our CEO JCTellier's perspective 👇   

📢 Our ESG ratings from both Sustainalytics and ISS have improved to respectively 13.7 and B- 🎉 Both looking at environmental, social and governance dimensions, these ratings reflect our progress towards advancing sustainable impact for a healthier future. Thank you to our partners and everyone at #TeamUCB for helping us rank among the top 10% of pharma companies worldwide. Together, we can continue making a positive difference for people with severe diseases and society as a whole. Learn more about our initiatives and impact here 👉https://lnkd.in/eBqwT7qX . #Sustainability #ESG 

🌐 A strong half-year start for UCB, setting the tone for our decade of growth! Our journey is just beginning, powered by a deep commitment to delivering differentiated solutions for people living with severe diseases. This commitment is bringing to life an impressive portfolio that is driving growth and success. Our robust financial performance and key regulatory milestones signal a promising future https://lnkd.in/euB5uiXZ Stay tuned for more updates! 

Uncontrolled #seizures can progress to more severe and complex types that require urgent, emergency care. Find out about Rapid and Early Seizure Termination (REST) and the new consensus recommendations published in EpiDisorders https://lnkd.in/eR5kbeRM

Hear from Konrad J. Werhahn, Head of Global Medical Affairs, Epilepsy & Rare Syndromes discuss how we’re exploring disease modification in #epilepsy research. Read more in Pharmafile.com https://lnkd.in/eCxrkz7V Credit: Pharmafocus, July/August 2024 © Samedan Ltd

In the latest article of our Exploring Epilepsies series, we’re exploring the unmet need in uncontrolled #seizures and the new Rapid and Early Seizure Termination (REST) concept outlined in EpiDisorders https://lnkd.in/eR5kbeRM

UCBCares® is the Service Center of UCB. We are here to answer your specific questions on your UCB medication and provide you with related information and materials. UCBCares® does not replace the conversation or the medical advice of the treating doctor or is not meant to promote the medicines of UCB. #UCBCares, #Neurology, #Neurologicalcondition

We're excited to share the latest updates on our groundbreaking gene therapy facility in Braine-l'Alleud, Belgium. This state-of-the-art facility not only represents a significant investment in Belgium but also stands as an epitome of innovation and environmental sustainability. This project broadens our horizons, allowing us to discover and develop revolutionary cures for severe diseases and enhance our development and manufacturing capabilities. Notably, it will create over 100 new highly skilled jobs. Join us in this exciting journey as we transform the future of disease treatment. For more details, please visit our career page https://lnkd.in/garwHTg While we are incredibly proud of the strides we've made, we understand that the path to groundbreaking advancements is paved with collective effort and collaboration. Our commitment to addressing the unmet needs of patients worldwide drives us forward every single day. We are deeply grateful to our dedicated team of scientists, researchers, and partners whose hard work and passion make milestones like this possible. As we continue this journey, we remain focused on not just the outcomes but also on the people whose lives we aim to transform. Together, we aspire to build a future where innovative treatments can offer hope and tangible benefits for those affected by severe diseases. Stay tuned for more updates as we progress, and thank you for being part of our mission. For more details, check out our latest story https://lnkd.in/eTXMNPN6 #Progress #Collaboration #Hope #GeneTherapy

Bart is an Upstream Process Lead Engineer working on UCB’s exciting Genesis project. Find out more about a day in his life as he innovates in the field of gene therapy now, and in the future.    Whether he’s taking the time for deep focus, connecting with colleagues over a freshly cooked lunch or running checks on equipment, his experience at UCB supports him and sets him up for success in his day-to-day activities and career.    At UCB we have a strong human focus. We’re committed to the wellbeing of our employee community and strive to make this a workplace where people enjoy meaning and balance.    https://lnkd.in/dHkyid5y #MakeYourMarkForPatients #TeamUCB #PharmaJobs